176 related articles for article (PubMed ID: 37293781)
1. Break to Build: Isothermal Assembly of Nucleic Acid Nanoparticles (NANPs)
Beasock D; Ha A; Halman J; Panigaj M; Wang J; Dokholyan NV; Afonin KA
Bioconjug Chem; 2023 Jun; 34(6):1139-1146. PubMed ID: 37293781
[TBL] [Abstract][Full Text] [Related]
2. Discriminating Immunorecognition Pathways Activated by RNA Nanostructures.
Danai L; Johnson MB; Afonin KA
Methods Mol Biol; 2023; 2709():229-240. PubMed ID: 37572284
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Intracellular Compartmentalization of RNA Nanostructures.
Radwan Y; Afonin KA; Johnson MB
Methods Mol Biol; 2023; 2709():211-228. PubMed ID: 37572283
[TBL] [Abstract][Full Text] [Related]
4. The immunorecognition, subcellular compartmentalization, and physicochemical properties of nucleic acid nanoparticles can be controlled by composition modification.
Johnson MB; Halman JR; Miller DK; Cooper JS; Khisamutdinov EF; Marriott I; Afonin KA
Nucleic Acids Res; 2020 Nov; 48(20):11785-11798. PubMed ID: 33091133
[TBL] [Abstract][Full Text] [Related]
5. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier.
Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA
Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786
[TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor-Mediated Recognition of Nucleic Acid Nanoparticles (NANPs) in Human Primary Blood Cells.
Hong E; Halman JR; Shah A; Cedrone E; Truong N; Afonin KA; Dobrovolskaia MA
Molecules; 2019 Mar; 24(6):. PubMed ID: 30897721
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects.
Johnson MB; Chandler M; Afonin KA
Adv Drug Deliv Rev; 2021 Jun; 173():427-438. PubMed ID: 33857556
[TBL] [Abstract][Full Text] [Related]
8. Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Juneja R; Vadarevu H; Halman J; Tarannum M; Rackley L; Dobbs J; Marquez J; Chandler M; Afonin K; Vivero-Escoto JL
ACS Appl Mater Interfaces; 2020 Sep; 12(35):38873-38886. PubMed ID: 32805923
[TBL] [Abstract][Full Text] [Related]
9. Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles.
Klotz K; Radwan Y; Chakrabarti K
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615420
[TBL] [Abstract][Full Text] [Related]
10. The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells.
Bila D; Radwan Y; Dobrovolskaia MA; Panigaj M; Afonin KA
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299506
[TBL] [Abstract][Full Text] [Related]
11. Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior.
Chandler M; Afonin KA
Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 31013847
[TBL] [Abstract][Full Text] [Related]
12. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution.
Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA
Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854
[TBL] [Abstract][Full Text] [Related]
13. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles.
Chandler M; Jain S; Halman J; Hong E; Dobrovolskaia MA; Zakharov AV; Afonin KA
Small; 2022 Nov; 18(46):e2204941. PubMed ID: 36216772
[TBL] [Abstract][Full Text] [Related]
14. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).
Ke W; Afonin KA
Adv Drug Deliv Rev; 2021 Sep; 176():113835. PubMed ID: 34144087
[TBL] [Abstract][Full Text] [Related]
15. The Application of Light-Assisted Drying to the Thermal Stabilization of Nucleic Acid Nanoparticles.
Anh Lam P; Furr DP; Tran A; McKeough RQ; Beasock D; Chandler M; Afonin KA; Trammell SR
Biopreserv Biobank; 2022 Oct; 20(5):451-460. PubMed ID: 36067075
[No Abstract] [Full Text] [Related]
16. Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights.
Rebolledo LP; Ke W; Cedrone E; Wang J; Majithia K; Johnson MB; Dokholyan NV; Dobrovolskaia MA; Afonin KA
ACS Appl Mater Interfaces; 2024 Feb; 16(7):8430-8441. PubMed ID: 38344840
[TBL] [Abstract][Full Text] [Related]
17. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs).
Nordmeier S; Ke W; Afonin KA; Portnoy V
Nanomedicine; 2020 Nov; 30():102285. PubMed ID: 32781137
[TBL] [Abstract][Full Text] [Related]
18. Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.
Tran AN; Chandler M; Halman J; Beasock D; Fessler A; McKeough RQ; Lam PA; Furr DP; Wang J; Cedrone E; Dobrovolskaia MA; Dokholyan NV; Trammell SR; Afonin KA
Small; 2022 Apr; 18(13):e2104814. PubMed ID: 35128787
[TBL] [Abstract][Full Text] [Related]
19. Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles.
Hong E; Halman JR; Shah AB; Khisamutdinov EF; Dobrovolskaia MA; Afonin KA
Nano Lett; 2018 Jul; 18(7):4309-4321. PubMed ID: 29894623
[TBL] [Abstract][Full Text] [Related]
20. Change in Lipofectamine Carrier as a Tool to Fine-Tune Immunostimulation of Nucleic Acid Nanoparticles.
Newton HS; Radwan Y; Xu J; Clogston JD; Dobrovolskaia MA; Afonin KA
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
